Identifying Diabetes and Impaired Glucose Tolerance in ICU Patients

NCT07261865 | Completed

• 1 other identifier: 20548
• Study Type: observational
• Target: 4,198
• Locations: 1 country
• Sites: 2

Brief Summary

In the Netherlands, patients admitted to the ICU are classified as having diabetes based on whether their medical records indicate glucose management medication use (Dutch National Intensive Care Evaluation (NICE) Registry). However, this approach does not identify patients with 1) undiagnosed diabetes, 2) uncontrolled diabetes, 3) patients managing their condition through lifestyle modifications, or 4) individuals with prediabetes, which is considered an early stage of diabetes. Consequently, this may lead to an underestimation of the "true" prevalence of chronic dysglycaemia among ICU patients and as a result the impact of various glycaemic states on acute outcomes remain underexplored.

Conditions

Diabetes (DM); Critical Illness

Keywords

Critical Illness; Diabetes; DISCOVER

Outcome Measures

Primary Outcomes (2)

• What is the prevalence of the various dysglycemic states in patients admitted to the ICU?

  HbA1c 6%=normal, 6-6.4%=prediabetes, \>6.5%=diabetes

  Day 1

• What is the impact of chronic hyperglycemic states on acute (ICU mortality and organ injury) and long-term outcomes?

  ICU mortality, organ injury during ICU stay (Acute Kidney Injury defined by the KDIGO criteria), and 1-year mortality

  Up to 1 year

Secondary Outcomes (1)

• Impact of relative dysglycemia

  Up to 1-year

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All adult patients admitted to the ICU

You may qualify if:

• All adult patients admitted to the ICU

You may not qualify if:

• None

Sponsors & Collaborators

• University Medical Center Groningen: lead
• Frisius Medisch Centrum: collaborator

Study Sites (2)

Frisius MC

Leeuwarden, Provincie Friesland, 8934AD, Netherlands

Location

University Medical Center Groningen

Groningen, Provincie Groningen, 9713GZ, Netherlands

Location

Related Publications (5)

• Luethi N, Cioccari L, Tanaka A, Kar P, Giersch E, Deane AM, Martensson J, Bellomo R. Glycated Hemoglobin A1c Levels Are Not Affected by Critical Illness. Crit Care Med. 2016 Sep;44(9):1692-4. doi: 10.1097/CCM.0000000000001656.

  PMID: 26977855 BACKGROUND

• Yong PH, Weinberg L, Torkamani N, Churilov L, Robbins RJ, Ma R, Bellomo R, Lam QT, Burns JD, Hart GK, Lew JF, Martensson J, Story D, Motley AN, Johnson D, Zajac JD, Ekinci EI. The Presence of Diabetes and Higher HbA1c Are Independently Associated With Adverse Outcomes After Surgery. Diabetes Care. 2018 Jun;41(6):1172-1179. doi: 10.2337/dc17-2304. Epub 2018 Mar 26.

  PMID: 29581095 BACKGROUND

• Torkamani N, Churilov L, Robbins R, Jerums G, Beik V, Radcliffe N, Patterson S, Bellomo R, Burns J, Hart GK, Lam Q, Power DA, MacIsaac RJ, Johnson DF, Zajac J, Ekinci EI. Diabetes and higher HbA1c levels are independently associated with adverse renal outcomes in inpatients following multiple hospital admissions. J Diabetes Complications. 2020 Jan;34(1):107465. doi: 10.1016/j.jdiacomp.2019.107465. Epub 2019 Oct 22.

  PMID: 31735639 BACKGROUND

• Michalia M, Kompoti M, Koutsikou A, Paridou A, Giannopoulou P, Trikka-Graphakos E, Clouva-Molyvdas P. Diabetes mellitus is an independent risk factor for ICU-acquired bloodstream infections. Intensive Care Med. 2009 Mar;35(3):448-54. doi: 10.1007/s00134-008-1288-0. Epub 2008 Sep 20.

  PMID: 18807006 BACKGROUND

• Carpenter DL, Gregg SR, Xu K, Buchman TG, Coopersmith CM. Prevalence and Impact of Unknown Diabetes in the ICU. Crit Care Med. 2015 Dec;43(12):e541-50. doi: 10.1097/CCM.0000000000001353.

  PMID: 26465219 BACKGROUND

MeSH Terms

Conditions

Diabetes Mellitus; Critical Illness

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Jill Moser, PhD

  University Medical Center Groningen

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 3 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: September 29, 2025
• First Posted: December 3, 2025
• Study Start: May 1, 2024
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: May 4, 2026

Record last verified: 2026-04

Locations

NL (2)